{
    "clinical_study": {
        "@rank": "129459", 
        "arm_group": [
            {
                "arm_group_label": "head & neck cancer patients, cisplatin treatment"
            }, 
            {
                "arm_group_label": "cancer patients, no cisplatin, no nephrotoxic agent"
            }
        ], 
        "biospec_descr": {
            "textblock": "urine and blood"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The project is designed to test new biomarkers that are more sensitive than the current\n      standard in detecting injury to the proximal kidney tubule and will establish better\n      criteria for when kidney safety concerns may halt further testing of a drug in humans."
        }, 
        "brief_title": "A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Acute Kidney Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will be conducted at four major medical centers, including the University of\n      Southern California, the University of Minnesota, the Dana Farber Cancer Institute, and the\n      MD Anderson Cancer Center.  Blood and urine samples will be collected from patients\n      undergoing treatment with either cisplatin or aminoglycosides, which are two different drugs\n      known to cause injuries to the proximal tubule of the kidney.  Cisplatin is a common\n      chemotherapy drug taken by patients with head and neck cancer.  Aminoglycosides are a common\n      antibiotic drug taken by patients with cystic fibrosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (Cisplatin Treatment Group):\n\n          1. Males and females \u2265 18 years of age\n\n          2. Diagnosis of head & neck cancer and confirmation that patient is due to receive a 1st\n             cycle of cisplatin (75-100 mg/m2/cycle) chemotherapy either:\n\n               -  as single agent chemotherapy in conjunction with local radiotherapy course, or\n\n               -  as part of the TPF combination (docetaxel, cisplatin, and fluorouracil)\n\n          3. Willingness and ability to comply with study procedures and study restrictions\n\n          4. Ability to provide written informed consent\n\n        Inclusion Criteria (Control Group):\n\n          1. Males and females \u2265 18 years of age\n\n          2. Diagnosis of head & neck cancer or similar condition such as an upper body, localised\n             malignancy. These control patients will be scheduled to receive a non-nephrotoxic\n             treatment modality (e.g. local radiotherapy alone)\n\n          3. Willingness and ability to comply with study procedures and study restrictions\n\n          4. Ability to provide written informed consent\n\n        Exclusion Criteria (All Subjects):\n\n          1. Chronic kidney disease defined by eGFR <60 mL/min/1.73m2. Patients with normal eGFR\n             but persistent dipstick proteinuria require urinary albumin measurement: those with\n             microalbuminuria (>30 mcg/mg creatinine) will be excluded\n\n          2. Patients currently receiving other potentially nephrotoxic agents (i.e. chronic use\n             of high dose NSAIDs, intravenous aminoglycosides, intravenous colistin, intravenous\n             vancomycin, or ACEi)\n\n          3. Any major surgery (i.e. high risk of acute kidney injury) in the previous month\n\n          4. Patients currently receiving trimethoprim or cimetidine or other medications known to\n             alter the tubular secretion of creatinine\n\n          5. Use of creatine supplements within 7 days prior to hospitalization\n\n          6. Solid organ transplant recipients\n\n          7. Abnormal liver function (serum ALT, AST or total bilirubin >2xULN)\n\n          8. Significant anemia (Hemoglobin < 10 g/dL)\n\n          9. Pregnancy\n\n         10. Institutionalized individuals"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "cancer patients"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936376", 
            "org_study_id": "Kidney Safety - Cisplatin"
        }, 
        "intervention_browse": {
            "mesh_term": "Cisplatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "kidney safety", 
            "biomarkers", 
            "serum creatinine", 
            "BUN", 
            "cystic fibrosis", 
            "head and neck cancer", 
            "renal injury", 
            "drug induced acute kidney injury", 
            "aminoglycoside", 
            "cisplatin", 
            "nephrotoxicity", 
            "biomarker qualification"
        ], 
        "lastchanged_date": "September 3, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Research Coordinator1"
                }, 
                "contact_backup": {
                    "last_name": "Research Coordinator2"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Harvard Medical School - Brigham and Women's Hospital"
                }, 
                "investigator": {
                    "last_name": "Sushrut Waikar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator1"
                }, 
                "contact_backup": {
                    "last_name": "Research Coordinator2"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Robert Haddad, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator1"
                }, 
                "contact_backup": {
                    "last_name": "Research Coordinator2"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas MD Anderson"
                }, 
                "investigator": [
                    {
                        "last_name": "Abdulla Salahudeen, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bonnie Glisson, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ala Abudayyeh, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers", 
        "overall_contact": {
            "email": "stefan.sultana@novartis.com", 
            "last_name": "Stefan Sultana, MD"
        }, 
        "overall_contact_backup": {
            "email": "jratay@fnih.org", 
            "last_name": "Jessica Ratay, MS", 
            "phone": "(301) 435-4038"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Texas MD Anderson", 
                "last_name": "Abdulla Salahudeen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dana-Farber Cancer Institute", 
                "last_name": "Sushrut Waikar, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "biomarker change from baseline", 
            "safety_issue": "No", 
            "time_frame": "up to 3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936376"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Foundation for the National Institutes of Health", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Southern California", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "M.D. Anderson Cancer Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Harvard Medical School - Brigham & Women's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Amgen", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "AstraZeneca", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Eli Lilly and Company", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Johnson & Johnson", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Pfizer", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Critical Path Institute - Predictive Safety Testing Consortium", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Foundation for the National Institutes of Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}